SeterusnyaPanduan seterusnya
AI dalam Pengesanan Penyakit Parkinson
industri
PANDUAN Industri
AI in hepatology can score liver-biopsy images, analyze ultrasound features or estimate waiting-list outcomes for transplant candidates.
Dengar panduan iniAI-diceritakan · ~3 min
It matters because each task uses different evidence and intended settings, and a model score cannot replace pathology review or transplant-team judgment.
Liver disease covers several distinct problems: fatty change, inflammation, fibrosis, cirrhosis and cancer. AI tools for hepatology therefore perform different tasks. Image models may analyze ultrasound or other scans for steatosis or fibrosis, while pathology systems score features on a liver biopsy. Risk models can also estimate outcomes for patients awaiting liver transplant. A result from one task should not be treated as evidence for another; a model that classifies biopsy slides does not automatically diagnose a patient from a routine ultrasound. A current example is AIM-NASH, an AI-based histology measurement tool qualified by the U.S. FDA as a drug-development tool for MASH clinical trials. It scores biopsy components including steatosis, inflammation and fibrosis. Pathologists remain responsible for final interpretation and review the whole slide and AI output before accepting or rejecting scores. This is a specific clinical-trial use, not a general-purpose diagnostic clearance. Research has also examined ultrasound-based fibrosis and fatty-liver assessment, comparing models with biopsy or other reference tests. Transplant allocation is a separate area: the GEMA-AI study trained and internally validated a liver-waitlist model using UK registry data and tested it externally with Australian patients. It estimated which candidates might face death or removal from the list within a defined period, and modeled different prioritization from existing scores. That study did not make GEMA-AI a universal allocation rule. Transplant decisions involve policy, equity, organ availability and multidisciplinary review. Across all these applications, model outputs need validation in the intended population and should be interpreted with clinical context.
A pathologist uses AIM-NASH in a MASH clinical trial, reviews the whole-slide image and accepts or rejects each AI score.
A research team evaluates an ultrasound model for fibrosis against biopsy results in a defined patient cohort.
A transplant center studies whether a machine-learning waitlist score prioritizes candidates differently from existing allocation models.
A clinician checks whether a reported fibrosis-risk score reflects the patient’s imaging, lab results and history before discussing next steps.
Liver AI may combine imaging, pathology, laboratory data and longitudinal outcomes in more integrated workflows. That could help standardize trial scoring or identify candidates needing review, but broader use needs prospective evaluation across sites and patient groups. Clinical trials and organ-allocation policies also require transparent, auditable decisions. Future systems should show their inputs and limits, preserve pathologist or transplant-team authority and demonstrate how any score changes care. A research tool should not be assumed to be a routine-care product without further validation.
Newsletter percuma
Tiga cerita AI yang disahkan setiap pagi hari bekerja, ditulis dalam Bahasa Inggeris biasa. Percuma selamanya, tiada iklan.
Satu e-mel setiap hari bekerja. Berhenti melanggan dalam satu klik. Kami tidak pernah menjual atau berkongsi alamat anda.
Uji diri anda
Maklum balas segera pada setiap jawapan, dan sijil yang boleh dikongsi dengan ID yang boleh disahkan sebaik sahaja anda lulus kursus.
Sokong pendidikan AI percuma. AI Understanding ialah pertubuhan bukan keuntungan 501(c)(3) — tiada iklan, tiada bayaran dinding, selamanya. Buat derma
AI in hepatology can score liver-biopsy images, analyze ultrasound features or estimate waiting-list outcomes for transplant candidates. It matters because each task uses different evidence and intended settings, and a model score cannot replace pathology review or transplant-team judgment.
FDA described AIM-NASH as a tool to assist pathologists scoring biopsy components in trials.
FDA says pathologists review the slide and may accept or reject the AI score.
The guide separates ultrasound imaging models from biopsy histology scoring.
GEMA-AI was developed for liver waitlist outcome prediction and prioritization research.
The GEMA-AI study evaluated a model, not a universal policy adoption.
Teruskan belajar
Lebih banyak panduan dipilih untuk topik ini
SeterusnyaPanduan seterusnya
AI dalam Pengesanan Penyakit Parkinson
industri